Hadassah

Hadassah, Palestinian, and German Triumvirate Rescues Children with Severe Immune Defects

Tuesday, May 17 2016

A tripartite collaboration initiated by the Hadassah Medical Center with Palestinian and German colleagues, dedicated to the discovery and characterization of congenital diseases of the immune system, has led to the discovery of a new genetic mutation, a new disease, and the first successful bone marrow transplant in the world to cure a child with this condition. This scientific journey was highlighted in the hematology journal, Blood and was chosen as one of the top ten research articles of the year by this prestigious publication.

In March of this year, Hadassah hosted the inaugural international conference of this collaboration, reports Dr. Polina Stepensky, head of the Pediatric Bone Marrow Transplantation Center in the Department of Pediatric Hemato-Oncology, who initiated the collaboration together with Prof. Dr. Klaus Warnatz of the University of Freiburg’s Center for Chronic Immunodeficiency in 2012. Over one hundred doctors, nurses, transplant coordinators, and technicians from hospitals all over Israel, the Palestinian Authority (Ramallah, Hebron, Bethlehem, Jericho, Jenin) and representatives from both the Israeli and Palestinian Ministries of Health attended the conference to share their latest experiences in clinical and basic research on pediatric immunological diseases.

Through this collaboration, “over 70 children have been diagnosed with specific immunodeficiency diseases and about 40 have received successful bone marrow transplants at Hadassah,” Dr. Stepensky says. The tripartite project is now managed by Dr. Stepensky, Prof. Warnatz, and Dr. Omar Abu Zaitoun of Nablus. “I have a long-standing collaboration with Palestinian physicians-- especially Dr. Omar Abuzaitoun,” relates Dr. Stepensky. At first, the children with immunological diseases are identified by dedicated Palestinian physicians.  Upon referral to Hadassah, Dr. Stepensky examines them and refers them to Prof. Orly Elpeleg, head of Hadassah’s Department of Genetic and Metabolic Diseases, for a comprehensive genetic analysis called whole exome sequencing. This sequencing is a novel revolutionary technology which searches through a person’s genes and finds variations in the “coding region” called exons. “Once we have the genetic results,” Dr. Stepensky explains, “we perform immunological studies, both here and more advanced studies in Germany. After the specific immunological genetic defect is identified, many of the young patients come to Hadassah for transplantation to cure them.” 

Over 10 articles highlighting the work of this collaborative project have been published in leading scholarly journals in the field of immunology.

In 2015, Dr. Stepensky and Prof. Warnatz received a trilateral grant from the German Research Foundation (DFG), the central, self-governing research funding organization in Germany, which funds and supports groundbreaking scientific research. The grant enabled them to mount the conference.

Eager to continue with this research journey, Dr. Stepensky notes: “This collaboration is an amazing example of opening new horizons in science and medicine, finding new friends and, together, identifying new genes and new genetic mutations, along with the mechanisms through which these genes malfunction—with the end result of curing many children.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 13 2019

Alzheimer’s Further Illuminated at Hadassah with New Exclusive Imaging Agent

The Hadassah Medical Organization, through its subsidiary SRY, has contracted to be the sole Israeli agent for General Electric to produce Vizamy, the company’s new radioactive imaging agent to detect, at an early stage, amyloid plaque, which has been linked to the development of Alzheimer’s disease.

READ MORE ›
alt_text

Friday, Aug 2 2019

New Thyroid Eye Disease Clinic at Hadassah Brings Integrated Care to New Mom

Miriam, 34, had just given birth to her third child, and, unlike the joy she felt after her first two births, she felt awful.

READ MORE ›
alt_text

Friday, Aug 2 2019

Eloxx Pharmaceuticals Announces New Drug Application for Clinical Trial in Cystic Fibrosis Patients

Professor Eitan Kerem, head of the Division of Pediatrics at the Hadassah Medical Organization, will serve as the Global Lead Investigator for this clinical trial.

READ MORE ›
alt_text

Wednesday, Jul 31 2019

Skin Cancer Treatment Enhanced in New Center for Dermatologic Surgery

Thanks to a donation by the Israeli businessman and philanthropist Morris Kahn, a major supporter of the Israeli moon spacecraft “Beresheet,” Hadassah Hospital Ein Kerem has just opened the new Center for Dermatologic Surgery, which offers Mohs surgery for patients with common types of skin cancer.

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More